Adult T-cell lymphoma/leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adult T-cell lymphoma/leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Selinexor, Ifosfamide, Etoposide, and Dexamethasone for Patients with Relapsed or Refractory Peripheral T-cell Lymphomas https://clinicaltrials.eu/trial/study-of-selinexor-ifosfamide-etoposide-and-dexamethasone-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ Wed, 29 Apr 2026 14:29:19 +0000 https://clinicaltrials.eu/trial/study-of-selinexor-ifosfamide-etoposide-and-dexamethasone-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ This clinical trial is focused on studying a type of cancer known as Peripheral T-cell Lymphoma, which has either returned after treatment or has not responded to previous treatments. The study is testing a combination of medications to see how well they work together. The medications being used in this study are Selinexor (also known by its code name KPT-330), Ifosfamide, Etoposide, and Dexamethasone. These medications are being tested together to see if they can help improve the condition of patients with this type of lymphoma.

The purpose of the study is to determine how effective this combination of medications is in treating the lymphoma. Participants in the study will receive these medications over a series of treatment courses. The study will monitor the response of the lymphoma to the treatment, looking for signs of improvement such as a reduction in the size of the cancer or a complete disappearance of the cancer. The study will also keep track of any side effects that participants may experience while taking these medications.

Throughout the study, participants will receive regular check-ups and tests to monitor their health and the progress of the treatment. The study aims to provide valuable information on whether this combination of medications can be a successful treatment option for patients with relapsed or refractory Peripheral T-cell Lymphoma. The results of this study could help improve future treatment options for this challenging condition.

]]> Study on Acalabrutinib and R-CHOP for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) https://clinicaltrials.eu/trial/study-on-acalabrutinib-and-r-chop-for-patients-with-diffuse-large-b-cell-lymphoma-dlbcl/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-on-acalabrutinib-and-r-chop-for-patients-with-diffuse-large-b-cell-lymphoma-dlbcl/ This clinical trial is focused on studying a type of cancer called Diffuse Large B-Cell Lymphoma (DLBCL). The study is investigating the effectiveness of a treatment that includes a medication called Acalabrutinib, which is also known by its code name ACP-196. This medication is being tested in combination with a standard chemotherapy regimen known as R-CHOP, which is commonly used to treat DLBCL. The trial aims to assess how well this combination works in patients with specific genetic changes, such as the MYD88 L265P and CD79A/B mutations, which are changes in the DNA that can affect how the cancer behaves.

The purpose of the study is to evaluate the effectiveness of the treatment in different groups of patients. Some patients will receive the combination of Acalabrutinib and R-CHOP, while others may receive additional Acalabrutinib treatment or a reduced number of R-CHOP cycles based on their response to the initial treatment. The study will also explore the impact of certain test results, such as PET/CT scans and ctDNA levels, which help in understanding how the cancer is responding to the treatment. PET/CT is a type of imaging test that helps visualize cancer activity in the body, and ctDNA refers to small fragments of DNA from the cancer that are found in the blood.

Participants in the study will follow a treatment plan that may last up to 18 months, depending on their response to the therapy. The study will monitor the progression of the disease and the overall survival of the participants. It will also track any side effects experienced during the treatment. The goal is to find the most effective treatment approach for patients with DLBCL, particularly those with specific genetic mutations, and to improve their chances of recovery.

]]>